drugset / Trial / NCT06439602
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Timeline
- Start
- 2024-06-26
- Primary completion
- 2026-03-20
- Completion
- 2026-04-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR882 | Unknown | 50 mg | Oral |
| Subject | AR882 | Unknown | 75 mg | Oral |